Pricing and Market Access Archives - Pharmaceutical Technology

Colombia’s president signs law to strengthen pharmaceutical sector

Daniela Morales — Tue, 20 Aug 2024 09:36:34 +0000

On July 2024, Colombia's President Gustavo Petro signed Law 2386 of 2024, which declared the pharmaceutical sector as strategic, at least in writing.

Casgevy: Launch sequence and price analysis of the first marketed CRISPR therapy

Alex Watt — Fri, 02 Aug 2024 14:02:43 +0000

In 2023, Casgevy was approved in the US to treat sickle cell disease (SCD), making it the first FDA-approved gene therapy to use CRISPR-based gene editing.

The US Biosecure Act threatens to destabilise the pharmaceutical industry

Cyrus Fan — Wed, 17 Jul 2024 13:01:43 +0000

In January, the US House Select Committee on the Strategic Competition between the US and the Chinese Communist Party introduced the Biosecure Act.

UK’s antibiotic subscription funding model – a route to market sustainability?

Janet Beal — Mon, 01 Jul 2024 09:53:18 +0000

On 8 May, the UK was the world's first government to formally implement a new model for the funding and support of novel antibiotic commercialisation.

Ukraine: a market access review over two years of war

Alex Watt — Fri, 07 Jun 2024 13:30:21 +0000

GlobalData compares how market access to healthcare in Ukraine has changed during the Russia-Ukraine conflict.

AIFA’s horizon scanning 2024 predictions suggest an influx of ATMPs

Eoin Ryan — Thu, 30 May 2024 14:29:05 +0000

In May 2024, Italy’s medicines agency AIFA published a strategic overview, detailing all new active substances that are potentially advancing towards EU marketing authorisation.

The privileged status of orphan medicines in Germany

Alex Watt — Fri, 26 Apr 2024 14:48:38 +0000

In Germany, new measures have come into effect as part of the GKV-FinStG Act in 2022 that put into question this market’s desirability for orphan drug developers.

India sees insignificant revision to price ceiling in 2024

Leyla Hasanzadeh — Tue, 16 Apr 2024 09:00:35 +0000

Lenmeldy becomes world’s most expensive drug

Aman Bansal — Tue, 02 Apr 2024 13:19:33 +0000

The gene therapy for MLD, Lenmeldy (also branded as Libmeldy in some markets), has become the most expensive drug on the market.

Defining the HTA landscape for France and Germany: 2019–2023

Alex Watt — Mon, 18 Mar 2024 15:56:55 +0000

Using GlobalData’s POLI & HTA database, analysis has been conducted that will provide insight into how the HTA landscape adapted between 2019 and 2023.